MUMBAI, India, July 30 -- Intellectual Property India has published a patent application (202621068658 A) filed by Dr. Jayshree Sadashiv Patil; Dr. Yogita Rahul Shelke; Dr. Pratibha Gopalrao Raundal; Ms. Bharti Laxman Ugale; and Smt. Asmita Akshay Adke on June 01, 2026, for Targeted Anticancer Chemical Composition Comprising Tumor Responsive Bioactive Nanoconjugates And Multi-Stage Therapeutic Delivery System.
Inventors include Dr. Jayshree Sadashiv Patil; Dr. Yogita Rahul Shelke; Dr. Pratibha Gopalrao Raundal; Ms. Bharti Laxman Ugale; and Smt. Asmita Akshay Adke.
The application for the patent was published on July 24, 2026, under issue no. 30/2026.
Abstract: ABSTRACT Targeted Anticancer Chemical Composition Comprising Tumor Responsive Bioactive Nanoconjugates and Multi-Stage Therapeutic Delivery System The present invention relates to a targeted anticancer chemical composition that includes tumor responsive bioactive nanoconjugates in conjunction with a multi-stage therapeutic delivery system for precision cancer therapy. The invention involves the use of one or more bioactive anticancer agents in functionalized nanocarriers, a tumor recognition module capable of selectively binding to cancer associated biomarkers, a tumor-microenvironment-responsive activation module, a controlled therapeutic release module, an intracellular delivery enhancement module, and a bioavailability optimization module. The composition is designed to be substantially stable in systemic circulation and to be selectively activated by tumor-specific physiological conditions such as acidic pH, high enzymatic activity, oxidative stress, or hypoxia. Upon activation, the composition allows for controlled intracellular release of therapeutic agents, thus enhancing tumor penetration, cellular uptake and reducing off-target toxicity. The integrated therapeutic architecture further enhances the pharmacokinetic performance, therapeutic efficacy and treatment precision, while overcoming the limitations associated with conventional anticancer therapies. The invention provides a sophisticated targeted therapeutic platform suitable for the treatment of primary, metastatic and therapy resistant cancers.
Disclaimer: Curated by HT Syndication.
